EXHIBIT 99


    CAUTIONARY STATEMENTS REGARDING "SAFE HARBOR" PROVISIONS
     OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995


     The Company is hereby filing a cautionary statement
identifying important factors that could cause the Company's
actual results to differ materially from those projected in
forward looking statements of the Company made by, or on behalf
of, the Company.

    -  Fluctuations in interest rates and foreign currency
       exchange rates.

    -  Competitive factors including technological advances
       attained by competitors; patents granted to competitors;
       new products of competitors coming to the market; generic
       competition as the Company's products mature. 
       
    -  Increased pricing pressure both in the United States and
       abroad from managed care buyers, institutions and
       government agencies.

    -  Government laws and regulations affecting domestic and
       international operations including, among other laws and
       regulations, those resulting from healthcare reform
       initiatives at the state and federal level, as well as
       those relating to trade, monetary and fiscal policies,
       taxes, price controls, and possible nationalization.

    -  Patent positions can be highly uncertain and patent
       disputes are not unusual.  An adverse result in a patent
       dispute can preclude commercialization of products or
       negatively impact sales of existing products.

    -  Uncertainties of the FDA approval process and the
       regulatory approval processes of foreign countries,
       including, without limitation, delays in approval of new
       products.

    -  Changes in the current tax law such as those currently
       being considered by the United States Congress which would
       amend the Section 936 income tax credit to completely
       phase out the income-based tax credit for those companies
       with operations in Puerto Rico, where the Company has a
       major manufacturing facility.

    -  Difficulties in product development.  Pharmaceutical
       product development is highly uncertain.  Products that
       appear promising in the early phases of development may
       fail to reach market for numerous reasons.  They may be
       found to be ineffective or to have harmful side effects in
       clinical or pre-clinical testing, they may fail to receive
       the necessary regulatory approvals, they may turn out not
       to be economically feasible because of manufacturing costs
       or other factors or they may be precluded from
       commercialization by the proprietary rights of others.

    -  Recalls of pharmaceutical products as a consequence of
       previously unknown side-effects or for other reasons may
       occur.

    -  Significant litigation adverse to the Company.






22533-1